Digital Pathology Partnerships Tempus launched an open source digital pathology consortium with Yale New Haven Health and leading cancer centers including MSKCC, signaling a growing ecosystem for AI enabled pathology. This creates joint sales opportunities with consortium member institutions and integrates AI pathology workflows with Tempus platform and Lens for oncology drug development.

WGS Clinical Enablement Tempus unveiled whole genome sequencing assay xH for upcoming clinical availability, creating a path to offer comprehensive genomic profiling and decision support across cancer programs. Target large academic medical centers and health systems building precision medicine programs; cross sell with Lens and Preview.

Rapid Insight Delivery Tempus Preview accelerates turnaround by delivering clinically meaningful insights quickly after orders, opening sales conversations with hospital systems and pathology labs seeking faster decision support; pair with existing data platforms to demonstrate ROI.

Enterprise Pharma Partnerships With revenue scale in the hundreds of millions and a customer base that includes large health systems and oncology focused centers, there are clear cross sell opportunities to pharma, biotech, and CROs for co development of AI enabled therapeutics and companion diagnostics, leveraging Lens and our open workflows.

Strategic Outreach Recent leadership hires and active presence at industry conferences indicate strong market visibility and partnership appetite; use these touchpoints to schedule executive outreach, co marketed pilots, and joint events with target institutions.